United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $218.00 to $240.00. They now have a "neutral" rating on the stock.
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales [Yahoo! Finance]
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $375.00 to $400.00. They now have an "outperform" rating on the stock.
United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $300.00 price target on the stock.